Raymond James analyst Elliot Wilbur previously said he was skeptical of media-driven speculation that Sanofi (SNY) was preparing to bid for Flexion (FLXN), but he views the appointment of Yamo Deniz, another former Sanofi executive, as Flexion's chief medical officer as one more reason to doubt the rumor. Deniz "joins a growing roster of hires" from Sanofi and Wilbur does not believe these individuals, who "would have the best firsthand knowledge of exactly what the buzz is on Zilretta from the Sanofi perspective," would join Flexion simply to rejoin Sanofi again. While he thinks "some deflation" of the takeout premium in the stock could follow this hiring, Wilbur keeps a Strong Buy rating on Flexion shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here